Recommended Cash Tender Offer for MedImmune by AstraZeneca

Pursuant to the merger agreement with MedImmune, Inc. announced on 23 April, AstraZeneca PLC announces that its wholly-owned subsidiary, AstraZeneca Biopharmaceuticals Inc., today commenced a cash tender offer to acquire all outstanding shares of MedImmune’s common stock, par value $0.01 per share, at a price of $58.00 per share. The tender offer is scheduled to expire at 12:00 Midnight, New York City time, on Thursday, May 31, 2007, unless extended. Details of the tender offer are contained in the documents that are being sent to MedImmune stockholders and will be posted on astrazeneca.com/astrazeneca.se.
-Ends-

3 May 2007

AstraZeneca
Media Enquiries
Steve Brown / Edel McCaffrey (London): +44 020 7304 5033/5034
Staffan Ternby (Sweden): 08 553 26107
Emily Denney (Wilmington): +1 302 885 3451

Analyst / Investor Enquiries
Jonathan Hunt /Mina Blair / Karl Hård (London): +44 020 7304 5087/5084/5322
Staffan Ternby (Sweden): 08 553 26107
Ed Seage / Jorgen Winroth (US): +1 302 886 4065/ (212) 579 0506

Merrill Lynch (Financial Adviser to AstraZeneca)
Richard Girling: +44 020 7628 1000

Deutsche Bank (Joint Corporate Broker to AstraZeneca)
Charlie Foreman: +44 020 7545 8000

Goldman Sachs (Joint Corporate Broker to AstraZeneca)
Phil Raper: +44 020 7774 1000